Ondasat Oral Solution contains Ondansetron 2mg per milliliter and is indicated for the prevention and treatment of nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative conditions. Ondansetron is a selective 5-HT3 receptor antagonist that acts by blocking serotonin receptors centrally in the chemoreceptor trigger zone and peripherally in the gastrointestinal tract, thereby inhibiting the emetic signaling pathways. This oral solution formulation allows for precise dosing and ease of administration, particularly in patients who have difficulty swallowing tablets. Ondasat Oral Solution is typically administered prior to the emetogenic stimulus and may be continued as needed based on clinical response. It is well tolerated, with common adverse effects including headache, constipation, and fatigue. Caution is advised in patients with hepatic impairment, and dose adjustments may be necessary. Ondansetron should be used with care in patients with a history of cardiac arrhythmias, as it may cause QT interval prolongation. Ondasat Oral Solution should be stored at controlled room temperature, protected from light and moisture. It is contraindicated in patients with hypersensitivity to ondansetron or any of the excipients. This product is intended for use under medical supervision to ensure safe and effective management of nausea and vomiting.